Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC-VF Phase 2 in Metastatic Androgen-Independent Prostate Cancer
NCT00078585Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Nov 2003
- Primary completion
- Jan 2006
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rilimogene galvacirepvec in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Bavarian Nordic. Primary endpoint: Progression-Free Survival. Started Nov 2003; status: completed.
02
Drugs
rilimogene galvacirepvec
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00078585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078585.